Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152705 | 1.00 | KDM4E (0.53) | KDM4EGAALMNAL3MBTL1POLB | |
| Syringate SCHEMBL159392 | 0.87 | CA12 (0.67) | KDM4EGAALMNAL3MBTL1POLB | |
| SCHEMBL5924237 | 0.87 | KDM4E (0.63) | KDM4EGAALMNAL3MBTL1POLB | |
| Hydrochloric Acid SCHEMBL9064595 | 0.85 | KDM4E (0.61) | KDM4EGAALMNAL3MBTL1POLB | |
| SCHEMBL18031417 | 0.84 | KDM4E (0.53) | KDM4EGAALMNAL3MBTL1POLB | |
| SCHEMBL30418756 | 0.84 | KDM4E (0.53) | KDM4EGAALMNAL3MBTL1POLB | |
| SCHEMBL13671457 | 0.84 | PKM (0.75) | LMNAL3MBTL1PKMCA12CA1 | |
| SCHEMBL14586763 | 0.84 | LMNA (0.75) | LMNAL3MBTL1PKMCA12CA1 | |
| SCHEMBL30594704 | 0.83 | KDM4E (0.77) | KDM4EGAALMNAL3MBTL1POLB | |
| SCHEMBL1465618 | 0.83 | KDM4E (0.77) | KDM4EGAALMNAL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118703180-A | Weighting agent with good suspension property and preparation method thereof | 古莱特科技股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU ENERGY AG (DE) | 2025-08-21 | — | — | US | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-118703180-A | Weighting agent with good suspension property and preparation method thereof | 古莱特科技股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118703180-A | Weighting agent with good suspension property and preparation method thereof | 古莱特科技股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115697994-B | Fused quinazoline derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | CMBLU PROJECKT AG (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11731945-B2 | Redox-active compounds and uses thereof | CMBLU ENERGY AG (DE) | 2023-08-22 | — | — | US | disclosed |
| CN-105408327-A | Substituted benzoxazoles | Bayer Pharma AG | 2016-03-16 | — | — | CN | disclosed |
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124405-A1 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | KDM4E 946/4885GAA 1059/4885LMNA 2188/4885 |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | KDM4E 623/4885GAA 1357/4885LMNA 1642/4885 |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | KDM4E 2948/4885GAA 987/4885LMNA 3212/4885 |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | KDM4E 2948/4885GAA 987/4885LMNA 3212/4885 |
| US-20250263384-A9 | REDOX-ACTIVE COMPOUNDS AND USES THEREOF | NOX4, NQO1, GPX1 | KDM4E 946/4885GAA 1059/4885LMNA 2188/4885 |
| US-11731945-B2 | Redox-active compounds and uses thereof | NOX4, NQO1, GPX1 | KDM4E 946/4885GAA 1059/4885LMNA 2188/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | KDM4E 2948/4885GAA 987/4885LMNA 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.